develop
effect
vaccin
particular
subunitbas
vaccin
emerg
middl
east
respiratori
syndrom
mer
caus
mer
coronaviru
merscov
provid
safest
mean
prevent
continu
spread
mer
human
camel
review
briefli
describ
structur
merscov
spike
protein
receptorbind
domain
rbd
discuss
current
statu
mer
vaccin
develop
illustr
strategi
use
develop
rbdbase
subunit
vaccin
mer
also
summar
current
avail
anim
model
merscov
propos
futur
direct
mer
vaccin
taken
togeth
review
assist
research
work
develop
effect
safe
subunit
vaccin
merscov
emerg
coronavirus
might
caus
futur
pandem
middl
east
respiratori
syndrom
mer
newli
emerg
infecti
diseas
caus
novel
mer
coronaviru
merscov
merscov
first
identifi
human
saudi
arabia
june
zaki
et
al
although
spread
merscov
among
human
limit
merscov
infect
link
sever
famili
cluster
healthcar
worker
memish
et
al
memish
et
al
provid
evid
humantohuman
transmiss
viru
merscov
demonstr
increas
trend
infect
sinc
first
identif
sporad
mer
case
report
least
countri
middl
east
africa
europ
asia
north
america
novemb
total
laboratoryconfirm
case
includ
death
mortal
rate
report
http
geograph
spread
rapid
increas
mer
case
past
sever
month
rais
concern
pandem
potenti
even
though
consequ
pandem
might
less
sever
caus
sever
acut
respiratori
syndrom
coronaviru
sarscov
anoth
led
worldwid
outbreak
peiri
et
al
practic
control
strategi
potenti
outbreak
merscovcaus
emerg
infecti
diseas
develop
effect
vaccin
becom
high
prioriti
number
studi
point
transmiss
host
merscov
report
batderiv
coronavirus
particularli
bat
coronaviru
close
phylogenet
relationship
merscov
dipeptidyl
peptidas
receptor
merscov
also
receptor
prefer
bat
human
merscov
adapt
use
human
addit
bind
bat
suggest
bat
potenti
natur
reservoir
merscov
bat
coronavirus
remain
threat
human
health
potenti
crossspeci
transmiss
annan
et
al
cui
et
al
ithet
et
al
memish
et
al
yang
et
al
addit
bat
camel
recent
becom
focu
studi
merscov
transmiss
sinc
merscov
neutral
antibodi
merscov
gene
fragment
identifi
dromedari
camel
infecti
merscov
recov
infect
camel
bries
et
al
chu
et
al
drosten
et
al
haagman
et
al
meyer
et
al
nowotni
kolodziejek
reusken
et
al
fact
human
infect
merscov
exposur
infect
camel
suggest
camel
like
intermedi
transmiss
host
merscov
recent
merscov
rna
fragment
detect
air
sampl
collect
barn
shelter
merscovinfect
camel
azhar
et
al
indic
possibl
airborn
transmiss
merscov
anim
human
although
spread
merscov
among
human
limit
ineffici
increas
infect
rate
among
healthcar
worker
month
april
http
www
whointcsrdiseasecoronaviru
infectionsarch
updatesen
rais
concern
futur
epidem
potenti
call
develop
effect
safe
vaccin
prevent
control
mer
hotez
et
al
merscov
belong
lineag
c
close
relationship
bat
coronavirus
first
known
lineag
c
associ
human
infect
chan
et
al
woo
et
al
merscov
positivesens
singlestrand
rna
viru
whose
genom
encod
four
major
structur
protein
includ
spike
protein
envelop
protein
e
membran
protein
nucleocapsid
protein
n
uniqu
function
fig
e
protein
transmembran
protein
form
ion
channel
viral
surfac
n
protein
interact
function
protein
n
molecul
encapsul
genom
rna
hurst
et
al
among
four
structur
protein
merscov
protein
play
import
role
viru
infect
pathogenesi
display
trimer
viral
membran
surfac
precursor
protein
cleav
two
noncoval
associ
subunit
distal
subunit
membraneanchor
subunit
merscov
subunit
contain
receptorbind
domain
rbd
includ
core
structur
accessori
subdomain
receptorbind
motif
rbm
subunit
consist
put
fusion
peptid
transmembran
domain
two
heptad
repeat
region
term
heptad
repeat
fig
chen
et
al
lu
et
al
wang
et
al
although
merscov
sarscov
share
similar
core
structur
maintain
conform
integr
rbm
differ
chen
et
al
li
et
al
receptor
recogn
coronavirus
distinct
differ
angiotensinconvert
enzym
function
receptor
sarscov
also
known
identifi
receptor
merscov
li
et
al
raj
et
al
crystal
structur
sarscov
rbd
complex
receptor
identifi
rbd
sarscov
residu
rbm
residu
li
et
al
crystal
structur
analysi
merscov
rbd
alon
complex
map
rbd
residu
respect
protein
merscov
rbm
span
residu
chen
et
al
lu
et
al
wang
et
al
fig
list
crystal
structur
sarscov
merscov
rbd
complex
respect
receptor
merscov
undergo
two
major
process
infect
target
cell
first
viru
bind
cellular
receptor
via
rbd
subunit
second
complex
subunit
form
fusion
core
lead
cellviru
membran
fusion
therebi
mediat
merscov
entri
target
cell
lu
et
al
therefor
like
sarscov
protein
protein
merscov
play
essenti
role
receptor
bind
membran
fusion
cell
entri
previous
demonstr
protein
specif
rbd
sarscov
play
essenti
role
develop
sar
vaccin
du
et
al
jiang
et
al
thu
expect
rbd
merscov
protein
import
target
develop
vaccin
mer
lu
et
al
et
al
antibodi
induc
sarscov
rbd
crossneutr
merscov
infect
sinc
differ
receptor
recogn
two
coronavirus
suggest
develop
safe
effect
mer
vaccin
high
prioriti
du
et
al
sinc
mer
newlyemerg
viral
diseas
vaccin
develop
clinic
use
howev
number
vaccin
candid
test
andor
proven
effect
vitro
preclin
studi
current
updat
mer
vaccin
develop
includ
possibl
develop
certain
vaccin
type
candid
mer
discuss
reveal
recombin
modifi
vaccinia
viru
ankara
mva
express
fulllength
merscov
protein
mvamerss
produc
neutral
antibodi
immun
mice
infect
merscov
cell
cultur
vitro
song
et
al
provid
basi
develop
viral
vectorbas
mer
vaccin
addit
fulllength
infecti
cdna
clone
merscov
construct
use
revers
genet
system
relev
infecti
virus
could
rescu
propag
vero
human
liver
cell
et
al
scobey
et
al
report
also
shown
fullgenom
sequenc
merscov
strain
exhibit
stabil
sequenti
passag
two
mammalian
cell
line
vero
african
green
monkey
kidney
human
lung
frey
et
al
studi
indic
potenti
develop
liveattenu
virus
mer
vaccin
candid
moreov
report
high
titer
specif
antibodi
neutral
activ
gener
mice
vaccin
nanoparticl
express
fulllength
merscov
protein
suggest
possibl
develop
nanoparticlebas
mer
vaccin
coleman
et
al
addit
aforement
vaccin
type
epitopebas
subunit
vaccin
also
show
promis
merscov
infect
investig
efficaci
exampl
recent
studi
sequenc
analysi
comput
predict
identifi
immunogen
conserv
epitop
wdypkcdra
rnadirect
rna
polymeras
protein
human
coronavirus
support
concept
design
develop
epitopebas
univers
vaccin
mer
sharmin
islam
addit
recombin
protein
contain
rbd
merscov
protein
abl
elicit
strong
neutral
antibodi
vaccin
rabbit
mice
respect
du
et
al
et
al
et
al
mou
et
al
reinforc
signific
develop
proteinbas
subunit
mer
vaccin
candid
vaccin
repres
first
step
control
prevent
merscov
infect
subunit
vaccin
defin
base
purifi
protein
peptid
consist
major
antigen
fragment
pathogen
hansson
et
al
subunit
vaccin
possess
varieti
advantag
includ
high
safeti
profil
minim
side
effect
inject
site
constant
immun
effect
welldefin
pathogen
fragment
du
et
al
zhang
et
al
although
report
merscov
rbdbase
subunit
vaccin
limit
subunit
vaccin
base
sarscov
rbd
extens
studi
test
sinc
occurr
sar
show
suffici
efficaci
strong
protect
sarscov
infect
variou
anim
model
du
et
al
du
et
al
et
al
zakhartchouk
et
al
therefor
summari
sarscov
rbdbase
subunit
vaccin
provid
use
inform
specif
guidanc
design
effect
rbdbase
subunit
vaccin
merscov
consider
evid
shown
sarscov
rbd
contain
multipl
conformationdepend
epitop
induc
highli
potent
neutral
antibodi
therefor
critic
neutral
determin
develop
sar
subunit
vaccin
et
al
et
al
believ
recombin
fusion
protein
rbdfc
contain
rbd
residu
sarscov
protein
fuse
human
fc
fragment
induc
strong
antibodi
respons
neutral
activ
elicit
longterm
protect
immun
immun
rabbit
mice
respect
complet
protect
immun
mice
sarscov
challeng
du
et
al
et
al
also
identifi
recombin
rbd
protein
residu
express
mammalian
cell
cho
insect
cell
escherichia
coli
respect
abl
elicit
suffici
neutral
antibodi
protect
immun
sarscov
challeng
immun
mice
among
mammalian
cellexpress
rbd
induc
higher
neutral
antibodi
respons
express
insect
cell
e
coli
system
du
et
al
du
et
al
moreov
rbd
capabl
induc
high
titer
protect
antirbd
antibodi
respons
immun
nonhuman
primat
strongli
neutral
proteinmedi
sar
pseudoviru
infect
target
cell
wang
et
al
furthermor
shown
choexpress
sarscov
rbd
protein
contain
residu
elicit
potent
neutral
antibodi
respons
immun
mice
complet
protect
immun
yeastexpress
protein
induc
strong
rbdspecif
neutral
antibodi
respons
pseudoviru
live
sarscov
infect
interestingli
recombin
rbd
protein
repres
strain
human
sarscov
palm
civet
sarscov
respect
elicit
strong
crossneutr
antibodi
immun
mice
rabbit
pseudovirus
express
protein
viru
strain
crossneutr
human
palm
civet
sarscov
rbdspecif
antibodi
suggest
rbdbase
sarscov
subunit
vaccin
abl
induc
broad
crossprotect
immun
human
anim
sarscov
variant
et
al
note
high
titer
rbdspecif
neutral
antibodi
persist
exist
recov
patient
threeyear
followup
studi
indic
rbd
sarscov
highli
immunogen
human
cao
et
al
thu
provid
basi
develop
effect
subunit
vaccin
prevent
sarscov
infect
human
current
rbdbase
subunit
vaccin
preclin
test
small
anim
primat
anim
challeng
model
anticip
manufactur
clinic
evalu
next
five
year
jiang
et
al
summari
suggest
paradigm
support
develop
merscov
subunit
vaccin
indic
rbd
merscov
import
target
develop
merscov
subunit
vaccin
like
sarscov
counterpart
induc
strong
neutral
antibodi
respons
merscov
infect
du
et
al
zhu
et
al
base
previou
experi
develop
sarscov
rbdbase
subunit
vaccin
rapidli
identifi
rbd
merscov
essenti
vaccin
target
mer
optim
merscov
rbd
region
identifi
critic
neutral
domain
among
five
rbd
fragment
test
induc
highest
neutral
antibodi
merscov
infect
et
al
progress
develop
merscov
rbdbase
subunit
vaccin
summar
identifi
rbd
merscov
initi
align
sequenc
merscov
protein
sarscov
protein
found
residu
merscov
protein
share
similar
core
structur
sarscov
rbd
increas
likelihood
rbd
merscov
might
locat
region
recombin
protein
contain
residu
merscov
protein
fuse
fc
fragment
human
igg
express
cultur
supernat
mammalian
cell
purpos
form
conform
structur
thu
increas
immunogen
du
et
al
expect
express
recombin
protein
abl
form
high
molecularweight
molecul
shown
nonboil
sampl
sdspage
fig
left
recogn
merscov
antibodi
fig
right
detect
bind
receptor
merscov
coimmunoprecipit
assay
reveal
protein
bound
significantli
solubl
cellassoci
cell
recogn
antibodi
respect
fig
elisa
flow
cytometri
analys
indic
bound
dosedepend
manner
du
et
al
data
suggest
express
recombin
protein
form
conform
structur
predict
acid
fragment
contain
merscov
rbd
evalu
immunogen
identifi
merscov
rbd
demonstr
express
recombin
protein
induc
merscov
rbdspecif
antibodi
mice
subcutan
sc
immun
two
vaccin
result
effect
neutral
merscov
infect
vero
cell
vitro
du
et
al
indic
region
may
serv
essenti
target
develop
mer
subunit
vaccin
merscov
mucos
pathogen
vaccin
induc
product
strong
mucos
immun
respons
repres
mucos
iga
would
increas
potenti
prevent
merscov
site
viru
infect
test
abil
identifi
merscov
rbd
potenti
mucos
vaccin
immun
mice
use
merscov
protein
via
intranas
pathway
compar
system
mucos
immun
respons
neutral
antibodi
induc
rout
elicit
sc
rout
evalu
humor
immun
respons
demonstr
intranas
boost
vaccin
induc
level
merscov
igg
antibodi
well
subtyp
high
induc
via
sc
rout
although
igg
antibodi
elicit
pathway
prove
rel
lower
elicit
sc
rout
singl
vaccin
et
al
similar
immun
sc
rout
intranas
vaccin
also
capabl
elicit
effect
longterm
igg
antibodi
respons
particularli
multipl
vaccin
fig
et
al
confirm
abil
induc
strong
humor
immun
respons
via
mucos
rout
comparison
mucos
immun
respons
illustr
intranas
vaccin
induc
significantli
higher
level
merscov
iga
antibodi
induc
sc
rout
immun
mous
lung
fig
although
iga
level
slightli
higher
immun
mous
sera
via
rout
compar
sc
rout
et
al
data
suggest
immun
merscov
protein
induc
strong
local
mucos
immun
respons
rout
rather
sc
rout
serum
neutral
antibodi
titer
intranas
vaccin
protein
maintain
level
similar
either
boil
denatur
nonboil
nondenatur
subject
sdspage
follow
coomassi
blue
stain
western
blot
use
antibodi
develop
laboratori
protein
molecular
weight
marker
kda
indic
left
b
coimmunoprecipit
western
blot
analysi
bind
receptor
merscov
left
cellassoci
cell
right
bind
affin
test
use
antihuman
monoclon
antibodi
gml
r
system
minneapoli
mn
polyclon
antibodi
c
comparison
longterm
humor
immun
respons
induc
protein
scand
inimmun
mice
mous
sera
collect
month
day
postlast
boost
data
present
mean
igg
endpoint
titer
standard
deviat
sd
five
mice
per
group
comparison
mucos
immun
respons
induc
protein
scand
inimmun
mice
mous
lung
wash
collect
day
postlast
boost
data
present
mean
iga
sd
five
mice
per
group
indic
signific
differ
group
group
p
comparison
neutral
antibodi
respons
merscov
infect
vero
cell
sera
e
lung
wash
f
mice
scand
invaccin
protein
neutral
antibodi
titer
express
reciproc
highest
dilut
sampl
complet
inhibit
virusinduc
cytopath
effect
cpe
least
well
sampl
collect
day
postlast
boost
data
present
mean
neutral
antibodi
titer
sd
five
mice
per
group
indic
signific
differ
group
group
p
cf
mice
inject
pb
plu
respect
adjuv
montanid
sc
poli
c
includ
control
data
present
mean
igg
sd
duplic
well
c
comparison
receptor
bind
affin
rbd
fragment
elisa
bind
show
dose
depend
data
present
mean
igg
sd
duplic
well
comparison
immunogen
rbd
fragment
immun
mice
mous
sera
collect
day
vaccin
data
present
mean
igg
endpoint
titer
sd
five
mice
per
group
indic
signific
differ
group
p
e
comparison
neutral
antibodi
respons
merscov
infect
vero
cell
rbd
fragmentimmun
mice
neutral
antibodi
titer
express
reciproc
highest
dilut
sera
complet
inhibit
virusinduc
cpe
least
well
mous
sera
collect
day
vaccin
data
present
mean
neutral
antibodi
titer
sd
five
mice
per
group
indic
signific
differ
group
p
sc
rout
boost
vaccin
fig
howev
worth
note
neutral
antibodi
significantli
higher
immun
mous
lung
neutral
merscov
infect
target
vero
cell
via
rout
rather
sc
rout
fig
potenti
higher
titer
mucos
iga
antibodi
induc
inimmun
mous
lung
et
al
note
protein
also
abl
elicit
merscov
cellular
immun
respons
immun
mous
spleen
et
al
indic
cellular
immun
respons
might
also
play
role
prevent
merscov
infect
importantli
sinc
rbdinduc
system
humor
mucos
immun
respons
neutral
antibodi
particular
correspond
protect
sarscov
infect
du
et
al
expect
neutral
antibodi
induc
merscov
rbd
protein
correl
well
inhibit
merscov
infect
nevertheless
base
abil
merscov
rbd
protein
induc
strong
system
mucos
immun
respons
neutral
activ
expect
merscov
rbdbase
vaccin
effect
safe
mucos
candid
prevent
merscov
infect
addit
identifi
acid
fragment
contain
residu
three
addit
fragment
respect
span
residu
merscov
protein
defin
merscov
rbd
group
chen
et
al
lu
et
al
mou
et
al
wang
et
al
also
shown
truncat
acid
fragment
span
protein
residu
merscov
serv
rbd
merscov
identifi
critic
neutral
domain
merscov
rbd
ideal
mer
vaccin
candid
compar
identifi
rbd
fragment
term
antigen
receptor
bind
immunogen
neutral
activ
order
recombin
protein
form
suitabl
conform
structur
maintain
suffici
bioactiv
fuse
merscov
rbd
fragment
fc
human
igg
express
protein
mammalian
cell
express
system
fig
previous
strategi
implement
prove
success
express
rbd
protein
sarscov
influenza
viru
du
et
al
du
et
al
li
et
al
expect
four
merscov
rbd
protein
design
respect
form
dimer
conform
structur
maintain
good
antigen
et
al
react
strongli
merscov
rbdspecif
monoclon
antibodi
develop
laboratori
fig
although
protein
bound
effici
cell
bind
affin
notabl
differ
one
protein
highest
activ
fig
notabl
also
maintain
stronger
immunogen
protein
test
induc
significantli
higher
igg
antibodi
respons
immun
mice
fig
well
subtyp
importantli
protein
shown
elicit
highest
neutral
antibodi
titer
infect
merscov
fig
et
al
studi
identifi
truncat
fragment
span
residu
merscov
rbd
critic
neutral
domain
thu
make
ideal
target
develop
subunit
vaccin
infect
merscov
et
al
identif
critic
neutral
rbd
fragment
provid
foundat
rapid
develop
effect
safe
subunit
vaccin
prevent
spread
merscov
human
transmiss
infect
camel
human
vaccin
candid
prove
effect
merscov
infect
vitro
cultur
condit
need
evalu
effect
anim
challeng
model
confirm
protect
immun
merscov
shown
caus
transient
lower
respiratori
tract
infect
rhesu
macaqu
infect
monkey
demonstr
clinic
sign
diseas
viru
replic
histolog
lesion
neutral
antibodi
gener
de
wit
et
al
yao
et
al
demonstr
monkey
use
test
efficaci
mer
candid
vaccin
howev
merscov
anim
model
afford
research
base
high
cost
purchas
maintain
monkey
make
particularli
urgent
develop
small
anim
model
merscov
infect
studi
shown
merscov
suscept
human
nonhuman
primat
cell
type
includ
human
vero
african
green
monkey
suscept
bhk
hamster
mous
ferret
primari
kidney
cell
chan
et
al
tao
et
al
van
doremalen
et
al
find
correspond
observ
merscov
infect
human
nonhuman
primat
replic
small
anim
syrian
hamster
mice
ferret
coleman
et
al
de
wit
et
al
devitt
raj
et
al
van
doremalen
et
al
although
small
anim
model
merscov
still
lack
devitt
research
made
great
progress
toward
identif
develop
effect
small
anim
model
merscov
infect
particular
shown
mice
suscept
merscov
infect
prior
transduct
adenovir
vector
express
receptor
merscov
human
infect
mice
develop
pneumonia
accompani
inflammatori
cell
infiltr
histopatholog
chang
thu
small
anim
model
provid
practic
platform
afford
mean
evalu
efficaci
current
merscov
vaccin
accordingli
transgen
mous
model
integr
human
gene
mous
genom
establish
sever
laboratori
http
expect
test
vaccin
efficaci
near
futur
develop
effect
vaccin
urgent
need
control
spread
emerg
merscov
infect
viral
vectorbas
liveattenu
virusbas
vaccin
potenti
provid
effect
immun
subunit
vaccin
offer
safest
mean
prevent
although
subunitbas
vaccin
might
induc
less
immunogen
vaccin
type
efficaci
significantli
improv
ration
design
base
structur
analysi
rbd
merscov
protein
identif
stabl
critic
neutral
fragment
rbd
elimin
nonneutr
epitop
immunofocus
et
al
overal
strategi
develop
merscov
rbdbase
subunit
vaccin
provid
use
inform
design
effect
vaccin
merscov
emerg
coronavirus
might
caus
futur
pandem
expect
develop
mer
candid
vaccin
test
efficaci
prevent
merscov
infect
vivo
afford
small
anim
model
merscov
becom
avail
serolog
neutral
respons
protein
merscov
sarscov
coronavirus
share
low
level
crossreact
within
andor
across
subgroup
advis
merscov
coronaviru
vaccin
design
consid
construct
chimer
protein
contain
neutral
epitop
variant
viru
strain
author
declar
conflict
interest
